Ultragenyx Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US90400D1081

SecurityRARE / Ultragenyx Pharmaceutical Inc.
InstitutionMan Group plc
Latest Disclosed Ownership213,352 shares
Latest Disclosed Value $ 4,469,725
Man Group plc reports 172.23% increase in ownership of RARE / Ultragenyx Pharmaceutical Inc.

On May 15, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 213,352 shares of Ultragenyx Pharmaceutical Inc. (US:RARE) valued at $4,469,724 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 78,371 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of 172.23% during the quarter. The current value of the position is $4,973,235 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 213,352 134,981 172.23 4,470 148.00 0.0081
2026-02-17 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 78,371 71,219 995.79 1,803 738.14 0.0031
2025-11-14 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 7,152 -177,025 -96.12 215 -96.79 0.0004
2025-08-14 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 184,177 -270,971 -59.53 6,697 -59.37 0.0128
2025-05-15 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 455,148 157,754 53.05 16,481 31.72 0.0418
2025-02-14 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 297,394 -29,809 -9.11 12,511 -31.17 0.0329
2024-11-14 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 327,203 -301,523 -47.96 18,176 -29.66 0.0473
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 628,726 475,085 309.22 25,841 260.24 0.0653
2024-05-15 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 153,641 65,830 74.97 7,173 70.83 0.0181
2024-02-14 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 87,811 4,199 404.69 0.0117
2023-11-14 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 832 -57.33 0.0026
2023-08-14 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 42,277 1,950 141.94 0.0060
2023-05-15 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 807 -54.46 0.0029
2023-02-14 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 38,211 3,773 10.96 1,770 24.12 0.0063
2022-11-14 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 34,438 1,426 -8.65 0.0066
2022-08-15 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,561 219.88 0.0066
2022-05-16 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,724 6,724 488 0.0017
2021-08-16 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -16,645 -100.00 0 -100.00
2021-05-17 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 16,645 -28,503 -63.13 1,895 -69.68 0.0083
2021-02-16 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 45,148 12,555 38.52 6,250 133.30 0.0274
2020-11-16 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 32,593 4,016 14.05 2,679 19.87 0.0105
2020-08-14 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 28,577 -8,771 -23.48 2,235 34.72 0.0113
2020-05-15 2020-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 37,348 -58,795 -61.15 1,659 -59.61 0.0107
2020-02-18 2019-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 96,143 44,797 87.25 4,107 87.02 0.0135
2019-11-14 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 51,346 -16,217 -24.00 2,196 -48.81 0.0082
2019-08-14 2019-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 67,563 -10,142 -13.05 4,290 -20.39 0.0155
2019-05-15 2019-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 77,705 34,662 80.53 5,389 188.03 0.0204
2019-02-14 2018-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 43,043 -6,341 -12.84 1,871 -50.37 0.0083
2018-11-14 2018-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 49,384 49,384 3,770 0.0138
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.